Business
Pulse Biosciences Clarifies Details of Recent S-3 Filing
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary
About this update from Pulse Biosciences, Inc
[{"type":"text","content":" HAYWARD, Calif.--(BUSINESS WIRE)--\nPulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today provided additional clarification regarding the details of the SEC form S-3 (“the filing”) filed August 11, 2023.\n\n\nThe only shares registered in the filing are those currently owned by the “selling securityholder”, identified as Robert W. Duggan, Executive Chairman of the Pulse Biosciences Board of Directors. The shares were received in connection to the May, 2023 private placement which effectively cancelled all prior indebtedness owned by the Company to Mr. Duggan, including the principal balance of $65 million and accrued and unpaid interest of approximately $250,000. No additional shares were authorized or registered by the Company. Mr. Duggan has informed the Company that he has no present intention to sell the shares registered in this prospectus, or any of his Pulse Biosciences holdings.\n\n\nMr. Duggan commented, “We are encouraged by the recent business progress and especially the preclinical study results achieved by the nsPFA cardiac ablation catheter and surgical ablation clamp devices. I believe there is a promising future ahead for Pulse Biosciences as we seek to advance the treatment of atrial fibrillation and am proud to continue my support of the Company both as Executive Chairman of the Board and as long-term shareholder.”\n\n\nAbout Pulse Biosciences®\n\n\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers.\n\n\nPulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other c...